Pricing Log in Create free account

AstraZeneca PLC (AZN) vs Eli Lilly and Company (LLY)

AstraZeneca PLC and Eli Lilly and Company are both Drug Manufacturers General companies. Eli Lilly and Company is the larger, with a market value of $1.28T against $289.8B — 4.4× the size. AstraZeneca PLC trades at the lower P/E: 26.3× against 44.5×. Eli Lilly and Company grew revenue faster over the last twelve months: 45.5% against 7.32%. Eli Lilly and Company has the higher net margin (31.9% vs 17.7%) and the higher return on invested capital (26.4% vs 12.3%). Both pay a dividend; AstraZeneca PLC yields more (1.71% vs 0.49%). Across the 23 metrics below, Eli Lilly and Company leads on 12 and AstraZeneca PLC on 11.

Valuation

Metric AZN LLY Drug Manufacturers General median
P/E 26.33 44.47 26.57
P/S 4.65 14.13 3.49
P/B 5.60 30.35 5.20
Price to free cash flow 45.85 55.90 21.34
EV/EBITDA 14.80 34.37 14.80
EV/Sales 5.03 14.70 4.09
Earnings yield 3.80% 2.25% 2.40%
Free cash flow yield 2.18% 1.79% 4.43%

Profitability

Metric AZN LLY Drug Manufacturers General median
Gross margin 81.94% 83.64% 73.01%
Operating margin 23.68% 40.27% 18.34%
Net margin 17.68% 31.90% 7.31%
Free cash flow margin 10.15% 22.74% 18.52%
Return on equity 22.56% 86.02% 5.80%
Return on assets 9.41% 20.97% 2.28%
Return on invested capital 12.31% 26.42% 6.26%

Growth

Metric AZN LLY Drug Manufacturers General median
Revenue growth (TTM) 7.32% 45.51% 6.72%
EPS growth (last fiscal year) 45.44% 95.99% 21.81%
Revenue growth, 5-year CAGR 17.15% 21.58% 4.75%
Net income growth, 5-year CAGR 26.19% 27.22% 0.00%

Health

Metric AZN LLY Drug Manufacturers General median
Debt to equity 0.61 1.17 0.63
Current ratio 1.01 1.39 1.39
Net debt to EBITDA 1.13 1.19 1.15

Dividend

Metric AZN LLY Drug Manufacturers General median
Dividend yield 1.71% 0.49% 2.31%
Payout ratio 0.45 0.22 0.59

Size

Metric AZN LLY Drug Manufacturers General median
Market cap 289.79b 1.28t 131.21b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack